In childhood acute lymphoblastic leukemia, genomic subtype, aneuploidy linked to risk for relapse
THURSDAY, Aug. 22, 2024 (HealthDay News) — Genetic subtype, aneuploidy patterns, and genomic alterations are associated with the risk for relapse in childhood acute lymphoblastic leukemia (ALL), according to a study published online Aug. 9 in the Journal of Clinical Oncology.
Ti-Cheng Chang, Ph.D., from St. Jude Children”s Research Hospital in Memphis, Tennessee, and colleagues performed genome and transcriptome sequencing of diagnostic and remission samples of children with standard-risk (SR; 1,381 children) or high-risk B-progenitor ALL with favorable cytogenetic features (115 children) to identify genomic determinants of relapse. The case-control study design analyzed 439 children who relapsed and 1,057 who remained in complete remission for five years or longer.
The researchers found an association for genomic subtype with relapse, which occurred in approximately 50 percent of the cases with PAX5-altered ALL (odds ratio [OR], 3.31). Favorable survival was seen in association with gain of chromosome 10 with disomy of chromosome 7 (OR, 0.27; St. Jude Children”s Research Hospital validation cohort: OR, 0.22), while disomy of chromosomes 10 and 17 with gain of chromosome 6 was associated with relapse (OR, 7.16; validation cohort OR, 21.32) within high-hyperdiploid ALL. Genomic alterations were associated with relapse in a subtype-dependent manner and were also associated with presence of minimal residual disease.
“As discussions about deintensification of therapy are underway, it is essential to comprehensively genotype newly diagnosed patients with SR ALL to accurately tailor the intensity of therapy to minimize the toxicity without increasing the risk of relapse,” the authors write.
Several authors disclosed ties to relevant organizations.
Heated Tobacco Products Are Not Biologically Inert 
Childhood Cancer Survivors Often Have Mental Distress in Adulthood 
Gene Mutation Identified That Increases Lung Cancer Risk 
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL 
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment 
Early Survivorship Care Linked to Improved Outcomes in Head, Neck Cancer .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy 
